Company intelligence / Profile preview
PurMinds NeuroPharma
Toronto, Ontario, Canadapurminds.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
PurMinds is developing novel therapeutics for neurological and neurodegenerative disorders. Their lead candidate PUR501 is a non-hallucinogenic neuroplastogen that has shown positive effects on structural neuroplasticity with minimal hallucinogenic capacity. The company also has a Health Canada Dealer's License for Controlled Drugs and Substances and supplies botanical psilocybin for research purposes.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculespsychedelic compoundsbotanical psilocybin
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Bluestem API Inc.
Beyond the preview
Go deeper on PurMinds NeuroPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PurMinds NeuroPharma.